Phibro Animal Health Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Phibro Animal Health in the last twelve months. There are currently 2 sell ratings for the stock. The consensus among Wall Street research analysts is that investors should "sell" Phibro Animal Health stock.
View analyst ratings for Phibro Animal Health or view top-rated stocks.

Wall Street analysts have given Phibro Animal Health a "Sell" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Phibro Animal Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Phibro Animal Health is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Phibro Animal Health.

Phibro Animal Health Co. (NASDAQ:PAHC) released its earnings results on Tuesday, August, 24th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.31 by $0.01. Phibro Animal Health had a trailing twelve-month return on equity of 23.68% and a net margin of 6.53%.
View Phibro Animal Health's earnings history.

Phibro Animal Health's stock was trading at $24.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PAHC stock has decreased by 12.3% and is now trading at $21.55.
View which stocks have been most impacted by COVID-19.

Phibro Animal Health declared a quarterly dividend on Monday, July 26th. Investors of record on Wednesday, September 1st will be paid a dividend of $0.12 per share on Wednesday, September 22nd. This represents a $0.48 annualized dividend and a dividend yield of 2.23%. The ex-dividend date of this dividend is Tuesday, August 31st.
View Phibro Animal Health's dividend history.

Phibro Animal Health pays an annual dividend of $0.48 per share and currently has a dividend yield of 2.22%. Phibro Animal Health does not yet have a strong track record of dividend growth. The dividend payout ratio of Phibro Animal Health is 38.71%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Phibro Animal Health will have a dividend payout ratio of 36.09% next year. This indicates that Phibro Animal Health will be able to sustain or increase its dividend.
View Phibro Animal Health's dividend history.

Phibro Animal Health issued an update on its FY 2022 earnings guidance on Wednesday, September, 15th. The company provided EPS guidance of $1.250-$1.320 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.340. The company issued revenue guidance of $840 million-$870 million, compared to the consensus revenue estimate of $850.23 million.

2 analysts have issued twelve-month price objectives for Phibro Animal Health's shares. Their forecasts range from $22.00 to $23.00. On average, they expect Phibro Animal Health's share price to reach $22.50 in the next year. This suggests a possible upside of 4.4% from the stock's current price.
View analysts' price targets for Phibro Animal Health or view top-rated stocks among Wall Street analysts.

4 employees have rated Phibro Animal Health CEO Jack Bendheim on Glassdoor.com. Jack Bendheim has an approval rating of 100% among Phibro Animal Health's employees. This puts Jack Bendheim in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Phibro Animal Health include 23andMe (ME), Prothena (PRTA), Nektar Therapeutics (NKTR), Insmed (INSM), PTC Therapeutics (PTCT), Cryoport (CYRX), ALX Oncology (ALXO), Zentalis Pharmaceuticals (ZNTL), Intra-Cellular Therapies (ITCI), Emergent BioSolutions (EBS), Amicus Therapeutics (FOLD), Apellis Pharmaceuticals (APLS), Aurinia Pharmaceuticals (AUPH), Cytokinetics (CYTK) and Agios Pharmaceuticals (AGIO).
View all of PAHC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Phibro Animal Health investors own include Zynga (ZNGA), Trevena (TRVN), Endo International (ENDP), Sonoma Pharmaceuticals (SNOA), Zynerba Pharmaceuticals (ZYNE), Intercept Pharmaceuticals (ICPT), VIVUS (VVUS), Zoetis (ZTS), Banco Bradesco (BBD) and Booking (BKNG).

Phibro Animal Health trades on the NASDAQ under the ticker symbol "PAHC."

Phibro Animal Health's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.38%), Vanguard Group Inc. (5.54%), Pzena Investment Management LLC (3.11%), State Street Corp (1.92%), Principal Financial Group Inc. (1.80%) and Renaissance Technologies LLC (1.64%). Company insiders that own Phibro Animal Health stock include E Thomas Corcoran and Larry Lee Miller.
View institutional ownership trends for Phibro Animal Health.

PAHC stock was sold by a variety of institutional investors in the last quarter, including Cove Street Capital LLC, BlackRock Inc., Smith Graham & Co. Investment Advisors LP, Renaissance Technologies LLC, Nuveen Asset Management LLC, AQR Capital Management LLC, Marshall Wace LLP, and Marshall Wace LLP.
View insider buying and selling activity for Phibro Animal Health or view top insider-selling stocks.

PAHC stock was bought by a variety of institutional investors in the last quarter, including Amundi, Pzena Investment Management LLC, Invesco Ltd., FMR LLC, Morgan Stanley, Morgan Stanley, Wells Fargo & Company MN, and First Trust Advisors LP.
View insider buying and selling activity for Phibro Animal Health or or view top insider-buying stocks.

Shares of PAHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PAHC stock can currently be purchased for approximately $21.55.

Phibro Animal Health has a market capitalization of $872.86 million and generates $833.40 million in revenue each year. The company earns $54.38 million in net income (profit) each year or $1.24 on an earnings per share basis.

Phibro Animal Health employs 1,700 workers across the globe.

The official website for Phibro Animal Health is www.pahc.com.

Phibro Animal Health is headquartered at GLENPOINTE CENTRE EAST 3RD FLOOR 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ, 07666.

Phibro Animal Health's mailing address is GLENPOINTE CENTRE EAST 3RD FLOOR 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ, 07666. The company can be reached via phone at (201) 329-7300 or via email at [email protected].